Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clearing the hurdles for CAR-T cell treatment.
Rouce RH. Rouce RH. Nat Rev Immunol. 2025 Sep 22. doi: 10.1038/s41577-025-01228-4. Online ahead of print. Nat Rev Immunol. 2025. PMID: 40983714 No abstract available.
Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecel.
Naik S, Selukar S, Talleur AC, Deshpande S, Llaurador Caraballo G, Fabrizio VA, Rouce RH, Zeng XL, Vatsayan A, Rossoff J, Pacenta HL, John S, Phillips CL, Talano JM, Moskop A, Verneris MR, Myers GD, Hall EM, Karras NA, Bonifant CL, Qayed M, Bakinowski E, Keating A, Baumeister SHC, Tomilson E, Hermiston ML, Satwani P, Krupski C, Chinnabhandar V, Stefanski HE, Egeler E, Curran KJ, Laetsch TW, Mackall CL, Prabhu S, Nguyen K, Baggott C, Schultz LM, McNerney KO. Naik S, et al. Among authors: rouce rh. Blood Adv. 2025 Jul 21:bloodadvances.2025016824. doi: 10.1182/bloodadvances.2025016824. Online ahead of print. Blood Adv. 2025. PMID: 40690779
Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry.
John S, Curran KJ, Hall EM, Keating A, Baumeister SHC, Nikiforow S, Driscoll T, Moskop A, McNerney KO, Phillips CL, Pulsipher MA, Hsieh EM, Rouce RH, Pasquini MC, Tiwari R, Willert J, Ramos RJ, Krueger J, Guest E, Grupp SA. John S, et al. Among authors: rouce rh. Blood Adv. 2025 Jun 24:bloodadvances.2025015881. doi: 10.1182/bloodadvances.2025015881. Online ahead of print. Blood Adv. 2025. PMID: 40554426
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis.
Pearson ADJ, Rossig C, Mackall CL, Shah NN, Baruchel A, Daems S, Anderson J, Biondi A, Bird N, Bodmer N, Brivio E, Buechner J, Calkoen FG, Cooper T, de Rojas T, Fox E, Gardner R, Ghorashian S, Heenen D, Ifversen M, Jacoby E, Juan M, Knox L, Komanduri K, Larghero J, Locatelli F, Ludwinski D, Majzner RG, McDonough J, Minard-Colin V, Nysom K, Pappo A, Park JR, Qasim W, Quintarelli C, Rives S, Rouce RH, Scobie N, Seitz C, Tasian SK, Weigel B, Weiner S, Zwaan CM, Vassal G. Pearson ADJ, et al. Among authors: rouce rh. Lancet Oncol. 2025 Apr;26(4):e214-e224. doi: 10.1016/S1470-2045(24)00736-8. Lancet Oncol. 2025. PMID: 40179917 Review.
50 results